Allergic skin disease, is a common occurrence amongst dogs and cats. Yet finding a solution for such patients is often a challenge.
Successful treatment often involves three components:
A combination of therapies to keep itching under control (i.e. a multimodal approach)
Good owner compliance by utilising cost effective and easy to administer products
Good tolerance from the patient ensuring they stay well, over what is often a lifelong issue
So, when presented with allergic skin disease – what do you chose for your patients?
With many different options available, successful protocols are as unique as the patient themselves. When considering the ideal combination of products - Redonyl Ultra provides a helpful addition to your patient’s current regimen, which complements and supports the fight against allergic dermatosis.
1. Noli C, et al (2015) Efficacy of ultramicronized palmitoylethanolamide in canine atopic dermatitis: an open-label multi-centre study. Veterinary Dermatology 26: 432-e101
2. Scarampella F, Abramo F, Noli C, (2001) Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Veterinary Dermatology 12, 29-39
3. Waisglass S. (2012) Palmitoylethanolamide and canine atopic dermatitis: a double-blind, randomized, placebo-controlled clinical trial. Proceedings SkinALIA 2012, Verona, Italy pp 57-61
4. Pistis M, Melis M, (2010) From surface to nuclear receptors: the endocannabinoid family extends its assets. Current Medicinal Chemistry 17(14):1450-67
5. Petrosino S, et al (2018) Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Frontiers in Pharmacology 20;9:249
6. Impellizzeri D, et al (2014) Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide. Journal of Neuroinflammation 11:136
7. Noli C, et al (2018) Ultramicronized palmitoylethanolamide prolongs the effect of a short-course of oral steroids in cats with non-flea hypersensitivity dermatitis and non-seasonal pruritis. A double blind, multicentre, randomised, placebo-controlled study. Veterinary Dermatology 29:368.
Seasonal Cases
In pets with a known seasonal pattern, e.g. animals that itch and develop itch skin lesions as a result of the pollination season, it is recommended that Redonyl Ultra is administered on an every-other-day schedule (PEA-um 10 mg/kg) at least 30 days prior to the start of allergy season. Then switch to daily administration if relapse occurs.
The disintegration time for each skittle is around 8 minutes for the 50 mg skittle and 12 minutes for the 150 mg capsule. In both cases by 4-5 minutes the capsule content starts to leak out from the sealing line.
One of the great benefits of Redonyl Ultra is that it can be used long term in 60 day cycles to be repeated as required. There is a long experience with long-term use in Italy, where the product has been available since 1997.
Redonyl Ultra can be used:
-
During the investigation period, when it is not yet clear what the diagnosis will be. It may take an extended time period until diagnosis can be confirmed, so until this point it is advised to administer the liquid only (i.e. to remove any potential interference from the gelatine capsule). If undertaking a diet trial as part of the investigative work up, we recommend administering Redonyl Ultra during the first month only, to allow evaluation of the patient during the second month.
We also recommend stopping Redonyl Ultra two weeks before intradermal skin testing.
- Before season with an atopic animal (seasonal atopy)
- In mild to moderate cases: It will not be enough if pruritus is severe (in these cases you might need to add steroids or other systemic treatment for short periods)
- In atopic animals that are not well controlled.
- In animals with conditions where standard treatments (glucocorticoids, ciclosporin) are contraindicated. Examples include patients with diabetes, Cushing’s disease, active/progressive tumours or those in immunocompromised states.
As canine atopic dermatitis is a lifelong condition it is important to have a treatment regimen that works for the individual patient. It is a good idea to feed a diet containing high levels of essential fatty acids and other substances that will improve skin barrier function. However, in some cases a diet may not be enough, therefore it is an excellent idea to include PEA-um into your patients dietary regimen.
Skin disease accounts for 20% of all consultations in general practice and pruritus represents over 30% of dermatology consultations.1 The primary diseases behind the skin symptoms are diverse. It is therefore important to ensure that you identify the underlying disease and decide on the right treatment. By using Dechra’s range of products, treatment can have a holistic approach in the control and maintenance of dermatological disease.